News & Events:SLS

Sellas Life Sciences Group Inc (SLS): * SELLAS LIFE SCIENCES REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE. * Sellas Life Sciences Group Inc (SLS)- QTRLY LOSS PER SHARE $1.05 Source text for Eikon: Further company coverage:

- Enhanced Pipeline with New Asset, GFH009, an In-licensed Next-Generation, Highly Selective CDK9 Inhibitor - - $25 Million of Gross Proceeds from Capital Raise in April 2022 and $1 Million Milestone Payment Received in May 2022 Add to Cash Balance of $14.3 Million as of March 31, 2022 - NEW YORK, May 12, 2022 -- SELLAS Life Sciences Group, Inc. (SLS), a late-stage clinical biopharmaceutical company ...

Sellas Life Sciences Group Inc (SLS): * SELLAS LIFE SCIENCES LAUNCHES EXPANDED ACCESS PROGRAM FOR GALINPEPIMUT-S Source text for Eikon: Further company coverage:

SELLAS Life Sciences Group, Inc. (SLS), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the Company has launched a Pre-Approval Access/Expanded Access Program with SELLAS’ lead asset, GPS, for treating patients suffering from acute myeloid leukemia.

For United Parcel Service Inc, Loop Capital upgraded the previous rating of Hold to Buy. According to WestPark Capital, the prior rating for Paysafe Ltd was changed from Hold to Buy. Baird upgraded the previous rating for H.B. Fuller Co from Neutral to Outperform. Morgan Stanley upgraded the previous rating for International Business Machines Corp from Equal-Weight to Overweight.

Sellas Life Sciences Group Inc (SLS): * SELLAS LIFE SCIENCES' NEWLY LICENSED GFH009 ASSET SHOWS SIGNIFICANT ANTI-LEUKEMIC EFFECT IN ACUTE MYELOID LEUKEMIA PATIENTS RELAPSED/REFRACTORY TO VENETOCLAX IN ONGOING PHASE 1 STUDY. * Sellas Life Sciences Group Inc (SLS) - FIFTH DOSE LEVEL COHORT OF GFH009, A HIGHLY SELECTIVE CDK9 INHIBITOR, INITIATED.

- Fifth Dose Level Cohort of GFH009, a Highly Selective CDK9 Inhibitor, Initiated - - No Dose-Limiting Toxicities in First Four Dose Levels - SELLAS Life Sciences Group, Inc. (SLS), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the first acute myeloid leukemia patient has enrolled in the fift...

Here's a roundup of top developments in the biotech space over the last 24 hours. Iovance Biotherapeutics, Inc. said the U.S. Food and Drug Administration on Friday provided a positive feedback regarding its proposed matrix of potency assays for its upcoming biologics license application for lifileucel in metastatic melanoma.

Sellas Life Sciences Group Inc (SLS): * SELLAS LIFE SCIENCES ANNOUNCES ACHIEVEMENT OF DEVELOPMENT MILESTONE FOR APPROVAL OF IND FOR GALINPEPIMUT-S IN CHINA Source text for Eikon: Further company coverage:

SELLAS Life Sciences Group, Inc. (SLS), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that an Investigational New Drug application to initiate the first clinical trial in China for 3D189, also known as SELLAS’ galinpepimut-S, has been approved by China’s National Medical Products Administration.

– In-licensed Next-Generation, Highly Selective CDK9 Inhibitor – – Closed Underwritten Public Offering with Gross Proceeds of $25 Million – – Appointed Robert Francomano as Chief Commercial Officer – – Completed Enrollment in Phase 1/2 Study of Galinpepimut-S in Combination with Merck’s KEYTRUDA® – – IND Application in China for Phase I Study of GPS Approved by China’s NMPA – – Shareholder Upda...

U.S. stocks pared gains, with the Nasdaq Composite turning lower toward the end of trading on Friday. The Dow traded up 0.16% to 34,732.60 while the NASDAQ fell 0.15% to 14,199.63. The S&P also fell, dropping, 0.01% to 4,529.95. Also check this: Alphabet And 3 Other Stocks Sold By Insiders Leading and Lagging Sectors Real estate shares jumped by 1.6% on Friday.

U.S. stocks traded slightly higher midway through trading following the release of non-farm payroll data for March. The Dow traded up 0.06% to 34,698.84 while the NASDAQ rose 0.34% to 14,269.29. The S&P also rose, gaining, 0.11% to 4,535.50. Also check this: Alphabet And 3 Other Stocks Sold By Insiders Leading and Lagging Sectors Energy shares jumped by 1.1% on Friday.

38 Stocks Moving In Friday's Mid-Day Session

U.S. stocks opened higher this morning following the release of non-farm payroll data for March. The Dow traded up 0.17% to 34,735.64 while the NASDAQ rose 0.30% to 14,262.94. The S&P also rose, gaining, 0.20% to 4,539.56. Also check this: Alphabet And 3 Other Stocks Sold By Insiders Leading and Lagging Sectors Energy shares jumped by 1.1% on Friday.

Here's a roundup of top developments in the biotech space over the last 24 hours. Reata Pharmaceuticals, Inc. said it has completed filing the rolling submission of a new drug application to the U.S. Food and Drug Administration for omaveloxolone for the treatment of patients with Friedreich's ataxia.

GenFleet Therapeutics has granted GFH009 rights to SELLAS Life Sciences Group Inc  across all therapeutic and diagnostic uses worldwide outside of Greater China. 

Sellas Life Sciences Group Inc (SLS): * SELLAS LIFE SCIENCES ANNOUNCES PRICING OF $25.0 MILLION UNDERWRITTEN PUBLIC OFFERING. * SELLAS -PRICING OF PREVIOUSLY ANNOUNCED OFFERING OF 4.6 MILLION COMMON SHARES & ACCOMPANYING WARRANTS EACH AT $5.40 PER SHARE & ACCOMPANYING WARRANT Source text for Eikon: Further company coverage:

SELLAS Life Sciences Group, Inc. (SLS), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the pricing of its previously announced underwritten public offering of 4,629,630 shares of its common stock and accompanying warrants to purchase up to 4,629,630 shares of common stock at a combined public offer...